2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)

The summary for the 2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)
	CFDA Number:	93.279
	CFDA Description:	Drug Abuse and Addiction Research Programs
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-DA-11-009
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Feb 03, 2011
	Creation Date:	Feb 03, 2011
	Original Closing Date for Applications:	Jun 27, 2011
	Current Closing Date for Applications:	Jun 27, 2011
	Archive Date:	Jul 28, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$1,500,000
	Federal Grant Award Ceiling:	$500,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2011 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-11-102. Applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified by April 26 of the opportunity to submit full applications under this FOA (DP1). The 2011 Avant-Garde awardees will be selected from this group of applicants.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-da-11-009.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1); • Pre-Application for the FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (X02); • Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the...; • 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance ...; • International Tobacco and Health Research and Capacity Building Program (R01); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • DRUG ABUSE ASPECTS OF HIV/AIDS AND OTHER INFECTIONS; • EPIDEMIOLOGY OF DRUG ABUSE; • PRESCRIPTION DRUG ABUSE; • MDMA: RESEARCH AREAS NEEDING MORE EMPHASIS